Cintas Analysts Increase Their Forecasts After Upbeat Earnings

Cintas Corporation (NASDAQ: CTAS) reported better-than-expected third-quarter financial results and raised FY24 guidance.

Cintas Corporation (NASDAQ:CTAS) reported better-than-expected third-quarter financial results and raised FY24 guidance.

Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company’s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from Benzinga Pro.

Todd M. Schneider, Cintas’ President, and Chief Executive Officer, stated, “Each of our operating segments continue to execute at a high level, which led to robust revenue growth of 9.9%, record high gross margin of 49.4%, record high operating margin of 21.6% and diluted EPS growth of 22.3%.”

Cintas increased FY24 annual revenue expectations from $9.48 billion-$9.56 billion to $9.57 billion-$9.60 billion (estimate: $9.56 billion). The firm raised EPS outlook from $14.35-$14.65 to $14.80-$15.00 (estimate: $14.60).

Cintas shares rose 0.1% to trade at $686.63 on Thursday.

These analysts made changes to their price targets on Cintas following earnings announcement.

  • Baird raised the price target on Cintas from $660 to $750. Baird analyst Andrew Wittmann maintained an Outperform rating.
  • B of A Securities increased the price target on Cintas from $700 to $790. B of A Securities analyst Heather Balsky maintained a Buy rating.
  • UBS boosted the price target on Cintas from $680 to $790. UBS analyst Joshua Chan maintained a Buy rating.
  • Truist Securities raised the price target on Cintas from $660 to $775. Truist Securities analyst Jasper Bibb maintained a Buy rating.
  • RBC Capital boosted the price target on Cintas from $675 to $725. RBC Capital analyst Ashish Sabadra maintained an Outperform rating.

 

Now Read This: Jim Cramer Likes Crown Castle, But Can’t Recommend Archer Aviation: It Has ‘No Earnings Power’

Total
0
Shares
Related Posts
Read More

Shift4 Payments Issued Response to Blue Orca Short Report Published Wednesday; CEO Jared Isaacman Said “I only purchased shares in 2022 and never sold stock on the market as it was implied.”

Dear Fellow Shareholders, As some of you may have seen, we were the subject of a short seller's report yesterday. Having founded this business when I was 16 and spending the last 24 years in constant pursuit of improvement, I am no stranger to critics. We knew long before our first day at the New York Stock Exchange that operating a public company attracts critics, both fairly and unfairly.

FOUR

Read More

Medical Cannabis Co. Expands Into National Grocery Chain: cbdMD’s Gummies Hit Shelves At Sprouts Farmers Market

cbdMD, Inc., a medical cannabis company, has entered into a partnership with Sprouts Farmers Market to make its Apple Cider Vinegar (ACV) and Immunity Gummy Pouches available in 175 locations nationwide. Sprouts Farmers Market has chosen cbdMD as a prominent brand for its CBD section. Shannon Charles, CMO at cbdMD, expressed their gratitude for this opportunity and their dedication to quality and customer satisfaction. The ACV Gummies contain organic apple cider vinegar powder and provide daily Vitamin B12 and Folic Acid requirements, while the Immunity Gummies support immune health with essential vitamins and antioxidants. The gummies are vegan-friendly, gluten-free, and compliant with the Farm Bill. Charles stated that this partnership brings them closer to their goal of promoting a balanced lifestyle and optimal wellness.

YCBD